Zymeworks Inc (ZYME)

14.13 -0.18 (-1.26%) USD  |  NASDAQ  |  Jan 08, 16:00
14.13 0.00 (0.00%) Pre-Market: 08:08
More

Zymeworks SG&A Expense (Quarterly): 13.90M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for ZYME.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc 3.244B
Ligand Pharmaceuticals Inc 24.48M
Cellectar Biosciences Inc 7.834M
Revance Therapeutics Inc 62.22M
CNS Pharmaceuticals Inc 1.384M